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concomitant radiochemotherapy in patients affected by head 
and neck cancer. 
 
Material and Methods: 226 patients, 38 female and 188 
male, with head and neck cancer, treated with 
chemoradiotherapy from 1995 to 2014 at our department, 
were retrospectively reviewed. 59,7% of patients were 
younger than 60 years. The anatomical sites of cancer were: 
36 nasopharynx, 63 oropharynx, 34 oral cavity, 51 larynx, 26 
hypopharynx, 16 others sites. 64 patients underwent to post-
operative treatment and 162 to radical treatment. They were 
treated with 2D-3DCRT (80%) or IMRT technique (20%). The 
mean dose administered was 68 Gy (range 60-74). The 
schedule of chemotherapy most used included cisplatin and 
5-FU. Acute and late toxicity are assessed according to 
CTCAE v.4.0 scale. Age, gender, tumor/nodal stage, primary 
site, tumor grading, RT technique and dose were assessed as 
potential prognostic factors influencing treatment toxicity. 
 
Results: Acute dysphagia and mucositis G2-3 were observed 
in 82,7% and 84,9% respectively of patients and were related 
with young age (p=0,03 and p=0,02), pharynx site (p=0,004 
and p<0,003) and advanced stage (p=0,02 and p=0,009). 
Acute xerostomia G2-3 (15%) was associated with 
oropharyngeal and oral cavity sites (p=0,03) and RT technique 
(p=0,004). Late xerostomia G2-3 (25,2%) was related with 
oropharyngeal site (p=0,04) and late fibrosis (14,1%) with 
nodal stage (p=0,005). Acute and late hearing loss (4,8%) was 
observed more frequently in nasopharyngeal cancer (p=0,03 
and p=0,001 respectively). 3,5% of patients had acute 
neurotoxicity and 4,8% late neurotoxicity; this adverse effect 
was associated with nasopharyngeal site (p=0,03 and p=0,03 
respectively). 
 
 
 
Conclusion: Clinical and technical data may be predictive of 
severe toxicity. Younger patients with pharynx cancer are 
more susceptible to dysphagia, mucositis and xerostomia. In 
this subset of patients it's critical evaluate strategies of 
adaptive radiotherapy with the aim to decrease the toxicity. 
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Purpose or Objective: To analyze clinical outcome and 
prognostic factors in a consecutive series of 160 non-
metastatic nasopharyngeal carcinoma (NPC) patients (pts) 
treated curatively with intensity modulated radiotherapy 
(RT) techniques (IMRT, Intensity Modulated Radiation Therapy 
or VMAT, Volumetric Modulated Arc Therapy) and 
chemotherapy (CT). 
 
Material and Methods: Pts were treated between October 
2004 and April 2014 at our institution. Median age at 
diagnosis was 49 years (range 18-92). According to WHO, 144 
patients (90%) were suffering from undifferentiated NPC, 5 
patients (3.1%), 3 patients (1.9%) and 8 patients (5%) were 
respectively affected by squamous cell carcinoma G1, G2 or 
G3. One pt was in stage I (0.6%), 31 pts (19.4%) were in stage 
II, 47 pts (29.4%) in stage III, 31 pts (19.4%) in stage IVA and 
50 pts (31.2%) in stage IVB. Seven pts (4.4%) received RT 
alone: 1 pt in stage I and 6 pts in stage II. Of the remaining 
153 pts (95.6%) (25 pts with stage II and 128 pts with stage III 
and IV) 34 patients (21.2%) received CT concomitant to RT 
and 119 patients (74.4%) were treated with induction CT 
followed by RT-CT. IMRT was given with standard 
fractionation at a total dose of 70 Gy. In 134 patients 
(83.75%) circulating plasma EBV-DNA has been measured 
before treatment using quantitative PCR. A dedicated 
software (VODCA, www.vodca.ch) was used to collect and 
analyze dosimetric parameters in 137 pts. 
 
Results: With a median follow up of 55.7 months (range 3.8 - 
118.7) actuarial rates at 2 and 5 years were respectively: 
overall survival (OS) 92.36% and 82.81%, disease-free survival 
(DFS) 83.1% and 77.2%, local control (LC) 92.17% and 90.43%, 
locoregional control (LRC) 94.78% and 93.04% and distant 
control (DC) 89.57% and 86.96%. At univariate analysis N 
stage (N0+N1+N2+N3a vs N3b) was found to be a prognostic 
factor for DM (p = 0.029). At multivariate analysis conducted 
on the following parameters: T stage, N stage, stage, RT 
technique , V95%, Dmean and D99% (relative to High Risk 
PTV), the stage of T (T1+T2+T3 vs T4) was found to be a 
prognostic factor for LRC (p = 0.035). Both at univariate and 
multivariate analysis the stage of T was found to be a 
prognostic factor for LC (p = 0.004 and .011 respectively) and 
N stage (N0+N1+N2 vs N3) for DM and RC. Pts with a V95% > 
90% had better LC (p=0.004) and DFS (p=0.047). Pts with a 
Dmean > 69 Gy had better LC (p=0.029). Pts with a D99% > 64 
Gy had better LC (p=0.008) and OS (p=0.004). The threshold 
value of 45 cc of GTV T (Gross Tumor Volume of the primary 
tumor) was prognostic for LC (p = 0.0095). The threshold 
value of 1500 copies of EBV-DNA was prognostic for DC (p = 
0.048). 
 
Conclusion: The intensified treatment of CT-IMRT / VMAT 
achieves excellent clinical outcomes. Besides traditional 
prognostic factors, we demonstrated the prognostic value of 
dosimetric parameters. Finally, for the first time in a non-
endemic area threshold values of GTV T and EBV-DNA 
prognostic for LC and DC respectively have been confirmed. 
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Purpose or Objective: Technological advances have enabled 
clinicians to explore dose escalation strategies in various 
tumor sites. Intermediate and high risk oropharyngeal 
cancers have unsatisfactory 3 year outcomes. The 
simultaneous integrated boost (SIB) technique with dose per 
fraction slightly higher than 2Gy offers the advantages of 
shortening the treatment time and increasing the biologically 
equivalent dose to the tumor. This retrospective study is 
aimed to evaluate the clinical outcome of radiation dose 
escalation to 18FDG PET/CT positive tumor and nodal sub 
volumes using the Simultaneous Integrated Boost (SIB) IMRT 
technique by means of Helical Tomotherapy (HT) in locally 
advanced Oropharyngeal cancer patients (pts). 
 
Material and Methods: 37 pts, median age 59 years (range: 
41-81), treated between 2005 and 2014, were evaluated. 
Reported stage were III-IVAB (4 and 33 respectively). HT was 
delivered with the SIB technique at different dose levels: 
69Gy (2.3 Gy/day) to the PET-positive volume (GTV-PET), 66 
